Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Abecma Market Revenue Outlook: What CAGR Is Expected Through 2030?
The historical period’s expansion was driven by impressive clinical results from CAR T therapies, an increase in multiple myeloma cases, a scarcity of treatment options for refractory patients, regulatory clearances granted for cell-based treatments, and the widespread uptake of these therapies by oncology centers.
The forecast period’s expansion is driven by moves into earlier treatment stages, enhanced production efficiency, greater funding for oncology research, an expanding pool of eligible patients, and the creation of next-generation CAR T therapies. Key developments shaping this period feature a growing preference for CAR T cell treatments, the broadening scope of sophisticated cell-based oncology, the surge in tailored cancer therapies, heightened application in patients with refractory multiple myeloma, and progress in autologous cell processing techniques.
Download A Free Sample Report For Comprehensive Market Insights:
Abecma Market Growth Drivers And Industry Catalysts
The growing incidence of multiple myeloma is anticipated to drive expansion in the abecma market moving forward. Multiple myeloma, a blood cancer impacting plasma cells—a type of bone marrow white blood cell—is becoming more common due to factors such as an aging population, enhanced diagnostic methods, and heightened disease awareness. Abecma, a CAR T-cell therapy, addresses multiple myeloma by employing genetically engineered immune cells to locate and eliminate cancerous plasma cells, providing a fresh treatment avenue for patients with relapsed or refractory disease. For example, the American Cancer Society, a US nonprofit focused on cancer eradication, reported in January 2024 that 35,780 myeloma cases were projected for 2024, up from 34,470 in 2022. Consequently, the rising prevalence of multiple myeloma propels the abecma market forward.
Abecma Market Segment Landscape And Growth Potential
The abecma market covered in this report is segmented –
1) By Indication: Multiple Myeloma, B-Cell Lymphoma (BCL), Acute Lymphoblastic Leukemia (ALL)
2) By End User: Adult, Geriatric
3) By Distribution Channel: Hospitals And clinics, Retail And Speciality Pharmacies, Online Pharmacies
Abecma Market Trends Influencing Long-Term Demand
Major players in the abecma market are concentrating on developing innovative therapies, such as chimeric antigen receptor T cell (CAR T) cell therapy, aimed at improving patient outcomes, more precisely targeting particular cancer types, and broadening the range of treatment choices for individuals suffering from relapsed or refractory multiple myeloma. CAR T cell therapy is a sophisticated immunotherapy approach primarily used to address certain cancers, including leukemia and lymphoma. This method involves genetically modifying a patient’s own T cells—a type of white blood cell—to enhance their ability to identify and eliminate cancer cells. For example, in March 2024, Bristol Myers Squibb, a pharmaceutical company based in the United States, secured approval from the European Commission (EC) for Abecma (idecabtagene vicleucel; ide-cel), a CAR T-cell therapy intended for adults with relapsed and refractory multiple myeloma. This authorization specifically applies to patients who have previously received at least two lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody, and whose disease has progressed after the most recent treatment.
Abecma Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the abecma market are Bristol-Myers Squibb
Access The Complete Abecma Market Report:
Abecma Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the abecma market in 2025. The regions covered in the abecma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model